* Vaxart Inc VXRT.OQ VXRT.O is expected to show a rise
in
quarterly revenue when it reports results on March 15.
* The South San Francisco California-based company is
expected to
report a 812.2% increase in revenue to $675 thousand from $74
thousand a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Vaxart Inc is for a
loss
of 23 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Vaxart Inc
is
$6.5, above its last closing price of $0.76.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.25 -0.24 -0.23 Beat 5.2
Jun. 30 2022 -0.22 -0.21 -0.23 Missed -9.5
Mar. 31 2022 -0.16 -0.16 -0.20 Missed -23.1
Dec. 31 2021 -0.17 -0.17 -0.17 Met 0
Sep. -0.15 -0.15 -0.14 Beat 4.5
30 2021
Jun. 30 2021 -0.14 -0.14 -0.13 Beat 8.8
Mar. 31 2021 -0.10 -0.10 -0.14 Missed -40
Dec. 31 2020 -0.05 -0.08 -0.13 Missed -62.5
This summary was machine generated March 13 at 20:11 GMT. All
figures in US dollars unless otherwise stated